Novel phenotypes of prediabetes?

Diabetologia

Volumn 59, Issue 9, 2016, Pages 1806-1818

  Häring, Hans Ulrich ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

Brain insulin resistance; Insulin; Liver fat; Phenotype; Prediabetes; Review; Secretion; Sensitivity

Indexed keywords

FETUIN A; INCRETIN; INSULIN; TRANSCRIPTION FACTOR 7 LIKE 2;

BODY FAT; BODY FAT DISTRIBUTION; BRAIN FUNCTION; EXERCISE; FATTY LIVER; FETAL BRAIN; GENETIC PREDISPOSITION; GENETIC VARIATION; HETEROZYGOTE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; OBESITY; PANCREAS DISEASE; PHENOTYPE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROGENY; REVIEW; ANIMAL; BRAIN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; PHENOTYPE; PREDIABETIC STATE;

EID: 84976292937     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4015-3     Document Type: Review

References (119)

1. Tuomilehto J, Lindström J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350
2. Knowler WC, Barrett-Connor E et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
3. Li G, Zhang P, Wang J et al (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371:1783–1789
4. Perreault L, Pan Q, Mather KJ et al (2012) Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379:2243–2251
5. Thamer C, Machann J, Stefan N et al (2007) High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. Obesity (Silver Spring) 15:531–538
6. Stefan N, Thamer C, Staiger H et al (2007) Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 92:1827–1833
7. Stefan N, Staiger H, Wagner R et al (2015) A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes. Diabetologia 58:2877–2884
8. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794
9. Ferrannini E (2014) Definition of intervention points in prediabetes. Lancet Diabetes Endocrinol 2:667–675
10. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846
11. Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51(Suppl 1):S212–S220
12. Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M (2009) Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58:1212–1221
13. Eriksson J, Franssila-Kallunki A, Ekstrand A et al (1989) Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337–343
14. Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359:2220–2232
15. Mohlke KL, Boehnke M (2015) Recent advances in understanding the genetic architecture of type 2 diabetes. Hum Mol Genet 24:R85–R92
16. DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium, Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2 Diabetes (SAT2D) Consortium et al (2014) Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 46:234–244
17. Wagner R, Hieronimus A, Lamprinou A et al (2014) Peroxisome proliferator-activated receptor gamma (PPARG) modulates free fatty acid receptor 1 (FFAR1) dependent insulin secretion in humans. Mol Metab 3:676–680
18. Wagner R, Staiger H, Ullrich S, Stefan N, Fritsche A, Häring HU (2014) Untangling the interplay of genetic and metabolic influences on beta-cell function: examples of potential therapeutic implications involving TCF7L2 and FFAR1. Mol Metab 3:261–267
19. Ordelheide AM, Gerst F, Rothfuss O et al (2013) Nor-1, a novel incretin-responsive regulator of insulin genes and insulin secretion. Mol Metab 2:243–255
20. Schäfer SA, Tschritter O, Machicao F et al (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50:2443–2450
21. Schäfer SA, Müssig K, Staiger H et al (2009) A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia 52:1075–1082
22. Müssig K, Staiger H, Machicao F et al (2009) Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes 58:1715–1720
23. Heni M, Ketterer C, Thamer C et al (2010) Glycemia determines the effect of type 2 diabetes risk genes on insulin secretion. Diabetes 59:3247–3252
24. Stefan N, Fritsche A, Häring H, Stumvoll M (2001) Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator—activated receptor-gamma2 gene. Diabetes 50:1143–1148
25. Wagner R, Kaiser G, Gerst F et al (2013) Reevaluation of fatty acid receptor 1 (FFAR1/GPR40) as drug target for the stimulation of insulin secretion in humans. Diabetes 62:2106–2111
26. Wagner R, Li J, Kenar E et al (2014) Clinical and non-targeted metabolomic profiling of homozygous carriers of transcription factor 7-like 2 variant rs7903146. Sci Rep 4:5296
27. Hribal ML, Presta I, Procopio T et al (2011) Glucose tolerance, insulin sensitivity and insulin release in European non-diabetic carriers of a polymorphism upstream of CDKN2A and CDKN2B. Diabetologia 54:795–802
28. Wagner R, Dudziak K, Herzberg-Schäfer SA et al (2011) Glucose-raising genetic variants in MADD and ADCY5 impair conversion of proinsulin to insulin. PLoS One 6, e23639
29. ‘t Hart LM, Simonis-Bik AM, Nijpels G et al (2010) Combined risk allele score of eight type 2 diabetes genes is associated with reduced first-phase glucose-stimulated insulin secretion during hyperglycemic clamps. Diabetes 59:287–292
30. Haupt A, Guthoff M, Schäfer SA et al (2009) The inhibitory effect of recent type 2 diabetes risk loci on insulin secretion is modulated by insulin sensitivity. J Clin Endocrinol Metab 94:1775–1780
31. Haupt A, Staiger H, Schäfer SA et al (2009) The risk allele load accelerates the age-dependent decline in beta cell function. Diabetologia 52:457–462
32. Groenewoud MJ, Dekker JM, Fritsche A et al (2008) Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia 51:1659–1663
33. Boesgaard TW, Zilinskaite J, Vänttinen M et al (2008) The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients—the EUGENE2 study. Diabetologia 51:816–820
34. Staiger H, Stancáková A, Zilinskaite J et al (2008) A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study. Diabetes 57:514–517
35. Stancáková A, Pihlajamäki J, Kuusisto J et al (2008) Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance. J Clin Endocrinol Metab 93:1924–1930
36. Staiger H, Machicao F, Schäfer SA et al (2008) Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS One 3, e3962
37. Staiger H, Machicao F, Kantartzis K et al (2008) Novel meta-analysis-derived type 2 diabetes risk loci do not determine prediabetic phenotypes. PLoS One 3, e3019
38. Kirchhoff K, Machicao F, Haupt A et al (2008) Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 51:597–601
39. Staiger H, Machicao F, Stefan N et al (2007) Polymorphisms within novel risk loci for type 2 diabetes determine beta-cell function. PLoS One 2, e832
40. Haupt A, Thamer C, Heni M et al (2010) Gene variants of TCF7L2 influence weight loss and body composition during lifestyle intervention in a population at risk for type 2 diabetes. Diabetes 59:747–750
41. Heni M, Herzberg-Schäfer S, Machicao F, Häring HU, Fritsche A (2012) Dietary fiber intake modulates the association between variants in TCF7L2 and weight loss during a lifestyle intervention. Diabetes Care 35, e24
42. Shu L, Sauter NS, Schulthess FT, Matveyenko AV, Oberholzer J, Maedler K (2008) Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 57:645–653
43. Pilgaard K, Jensen CB, Schou JH et al (2009) The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 52:1298–1307
44. Villareal DT, Robertson H, Bell GI et al (2010) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 59:479–485
45. Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163
46. Zimdahl H, Ittrich C, Graefe-Mody U et al (2014) Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia 57:1869–1875
47. Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250
48. Wegner L, Hussain MS, Pilgaard K et al (2008) Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins. Clin Endocrinol Metab 93:4013–4019
49. Alibegovic AC, Sonne MP, Højbjerre L et al (2010) The T-allele of TCF7L2 rs7903146 associates with a reduced compensation of insulin secretion for insulin resistance induced by 9 days of bed rest. Diabetes 59:836–843
50. Daniele G, Gaggini M, Comassi M et al (2015) Glucose metabolism in high-risk subjects for type 2 diabetes carrying the rs7903146 TCF7L2 gene variant. J Clin Endocrinol Metab 100:E1160–E1167
51. Le Bacquer O, Kerr-Conte J, Gargani S et al (2012) TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals. Diabetologia 55:2677–2681
52. Machann J, Thamer C, Stefan N et al (2010) Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology 257:353–363
53. Thamer C, Machann J, Staiger H et al (2010) Interscapular fat is strongly associated with insulin resistance. J Clin Endocrinol Metab 95:4736–4742
54. Rittig K, Staib K, Machann J et al (2008) Perivascular fatty tissue at the brachial artery is linked to insulin resistance but not to local endothelial dysfunction. Diabetologia 51:2093–2099
55. Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168:1609–1616
56. Kantartzis K, Machann J, Schick F et al (2011) Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia 54:864–868
57. Stefan N, Häring HU, Hu FB, Schulze MB (2013) Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 1:152–162
58. Stefan N, Häring HU (2011) The metabolically benign and malignant fatty liver. Diabetes 60:2011–2017
59. Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465
60. Kantartzis K, Peter A, Machicao F et al (2009) Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58:2616–2623
61. Peter A, Kovarova M, Nadalin S et al (2014) PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans. Diabetologia 57:2103–2107
62. Kovarova M, Königsrainer I, Königsrainer A et al (2015) The genetic variant I148M in PNPLA3 is associated with increased hepatic retinyl-palmitate storage in humans. J Clin Endocrinol Metab 100:E1568–E1574
63. Stefan N, Häring HU (2013) The role of hepatokines in metabolism. Nat Rev Endocrinol 9:144–152
64. Stefan N, Häring HU (2013) Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19:394–395
65. Stefan N, Schick F, Häring HU (2014) Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371:2236–2237
66. Stefan N, Fritsche A, Weikert C et al (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57:2762–2767
67. Weikert C, Stefan N, Schulze MB et al (2008) Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 118:2555–2562
68. Dasgupta S, Bhattacharya S, Biswas A et al (2010) NF-kB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem J 429:451–462
69. Takata H, Ikeda Y, Suehiro T et al (2009) High glucose induces transactivation of the alpha2-HS glycoprotein gene through the ERK1/2 signaling pathway. J Atheroscler Thromb 16:448–456
70. Lee J, Hong SW, Park SE et al (2015) Exendin-4 inhibits the expression of SEPP1 and fetuin-A via improvement of palmitic acid-induced endoplasmic reticulum stress by AMPK. Endocrinol Metab (Seoul) 2015:177–184
71. Srinivas PR, Wagner AS, Reddy LV et al (1993) Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 7:1445–1455
72. Siegel-Axel DI, Ullrich S, Stefan N et al (2014) Fetuin-A influences vascular cell growth and production of proinflammatory and angiogenic proteins by human perivascular fat cells. Diabetologia 57:1057–1066
73. Pal D, Dasgupta S, Kundu R et al (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18:1279–1285
74. Yudkin JS, Eringa E, Stehouwer CD (2005) “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365:1817–1820
75. Meijer RI, Serne EH, Smulders YM, van Hinsbergh VW, Yudkin JS, Eringa EC (2011) Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease. Curr Diab Rep 11:211–217
76. Rittig K, Dolderer JH, Balletshofer B et al (2012) The secretion pattern of perivascular fat cells is different from that of subcutaneous and visceral fat cells. Diabetologia 55:1514–1525
77. Wagner R, Machann J, Lehmann R et al (2012) Exercise-induced albuminuria is associated with perivascular renal sinus fat in individuals at increased risk of type 2 diabetes. Diabetologia 55:2054–2058
78. Stefan N, Artunc F, Heyne N, Machann J, Schleicher ED, Häring HU (2016) Obesity and renal disease: not all fat is created equal and not all obesity is harmful to the kidneys. Nephrol Dial Transplant 31:726–730
79. Heni M, Machann J, Staiger H et al (2010) Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes Metab Res Rev 26:200–205
80. Stefan N, Sun Q, Fritsche A et al (2014) Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies. PLoS One 9, e92238
81. Silbernagel G, Kovarova M, Cegan A et al (2012) High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. J Clin Endocrinol Metab 97:E2288–E2292
82. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC (2011) Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 93:1048–1052
83. Ryan MC, Abbasi F, Lamendola C, Carter S, McLaughlin T (2007) Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 30:1075–1080
84. Utzschneider KM, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft S (2013) Beneficial effect of a weight-stable, low fat/ low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br J Nutr 109:1096–1104
85. Cussons AJ, Watts GF, Mori TA, Stuckey BG (2009) Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 94:3842–3848
86. Scorletti E, Bhatia L, McCormick KG et al (2014) Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study. Hepatology 60:1211–1221
87. Stefan N, Machicao F, Staiger H et al (2005) Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 48:2282–2291
88. Thamer C, Machann J, Stefan N et al (2008) Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab 93:1497–1500
89. Hawley JA, Hargreaves M, Joyner MJ, Zierath JR (2014) Integrative biology of exercise. Cell 159:738–749
90. Osler ME, Fritz T, Caidahl K et al (2015) Changes in gene expression in responders and nonresponders to a low-intensity walking intervention. Diabetes Care 38:1154–1160
91. Kantartzis K, Thamer C, Peter A et al (2009) High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58:1281–1288
92. Böhm A, Weigert C, Staiger H, Häring HU (2016) Exercise and diabetes: relevance and causes for response variability. Endocrine 51:390–401
93. Stephens NA, Xie H, Johannsen NM, Church TS, Smith SR, Sparks LM (2015) A transcriptional signature of ‘exercise resistance’ in skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 64:999–1004
94. Boulé NG, Weisnagel SJ, Lakka TA et al (2005) Effects of exercise training on glucose homeostasis: the HERITAGE Family Study. Diabetes Care 28:108–114
95. Hoene M, Runge H, Häring HU, Schleicher ED, Weigert C (2013) Interleukin-6 promotes myogenic differentiation of mouse skeletal muscle cells: role of the STAT3 pathway. Am J Physiol Cell Physiol 304:C128–C136
96. Scheler M, Irmler M, Lehr S et al (2013) Cytokine response of primary human myotubes in an in vitro exercise model. Am J Physiol Cell Physiol 305:C877–C886
97. Hansen JS, Zhao X, Irmler M et al (2015) Type 2 diabetes alters metabolic and transcriptional signatures of glucose and amino acid metabolism during exercise and recovery. Diabetologia 58:1845–1854
98. Weigert C, Lehmann R, Hartwig S, Lehr S (2014) The secretome of the working human skeletal muscle—a promising opportunity to combat the metabolic disaster? Proteomics Clin Appl 8:5–18
99. Havrankova J, Brownstein M, Roth J (1981) Insulin and insulin receptors in rodent brain. Diabetologia 20(Suppl):268–273
100. Havrankova J, Roth J, Brownstein M (1978) Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272:827–829
101. Brüning JC, Gautam D, Burks DJ et al (2000) Role of brain insulin receptor in control of body weight and reproduction. Science 289:2122–2125
102. Okamoto H, Nakae J, Kitamura T, Park BC, Dragatsis I, Accili D (2004) Transgenic rescue of insulin receptor-deficient mice. J Clin Invest 114:214–223
103. Lin X, Taguchi A, Park S et al (2004) Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 114:908–916
104. Tschritter O, Preissl H, Hennige AM et al (2006) The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A 103:12103–12108
105. Heni M, Kullmann S, Preissl H, Fritsche A, Häring HU (2015) Impaired insulin action in the human brain: causes and metabolic consequences. Nat Rev Endocrinol 11:701–711
106. Kullmann S, Heni M, Veit R et al (2015) Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults. Diabetes Care 38:1044–1050
107. Heni M, Wagner R, Kullmann S et al (2014) Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men. Diabetes 63:4083–4088
108. Guthoff M, Grichisch Y, Canova C et al (2010) Insulin modulates food-related activity in the central nervous system. J Clin Endocrinol Metab 95:748–755
109. Grichisch Y, Çavuşoğlu M, Preissl H et al (2012) Differential effects of intranasal insulin and caffeine on cerebral blood flow. Hum Brain Mapp 33:280–287
110. Heni M, Kullmann S, Ketterer C et al (2012) Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and reward-related human brain regions. Diabetologia 55:1773–1782
111. Kullmann S, Frank S, Heni M et al (2013) Intranasal insulin modulates intrinsic reward and prefrontal circuitry of the human brain in lean women. Neuroendocrinology 97:176–182
112. Tschritter O, Preissl H, Hennige AM et al (2012) High cerebral insulin sensitivity is associated with loss of body fat during lifestyle intervention. Diabetologia 55:175–178
113. Scherer T, Lindtner C, O’Hare J et al (2016) Insulin regulates hepatic triglyceride secretion and lipid content via signaling in the brain. Diabetes. doi:10.2337/db15-1552
114. Kleinridders A, Ferris HA, Cai W, Kahn CR (2014) Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63:2232–2243
115. Pocai A, Lam TK, Gutierrez-Juarez R et al (2005) Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434:1026–1031
116. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L (2002) Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 5:566–572
117. Gancheva S, Koliaki C, Bierwagen A et al (2015) Effects of intranasal insulin on hepatic fat accumulation and energy metabolism in humans. Diabetes 64:1966–1975
118. Linder K, Schleger F, Ketterer C et al (2014) Maternal insulin sensitivity is associated with oral glucose-induced changes in fetal brain activity. Diabetologia 57:1192–1198
119. Linder K, Schleger F, Kiefer-Schmidt I et al (2015) Gestational diabetes impairs human fetal postprandial brain activity. J Clin Endocrinol Metab 100:4029–4036